Canaccord analyst Kyle Mikson initiated coverage of Seer with a Buy rating and $4 price target. The firm says the company offers an "unbiased proteomics platform that seamlessly integrates into existing mass spectrometry workflows." Seer is positioned to redefine the scale and economics of large-scale proteomics workflows, given its "first-mover advantage" in nanoparticle-based sample preparation and relatively limited direct competition, the analyst tells investors in a research note. It believes the stock does not reflect the company's growth potential.
